Jennifer Le-Rademacher

27PUBLICATIONS
84CO-AUTHORS
ChemotherapyWomen's studies (incl. girls' studies)Predictive and prognostic markersArts therapyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|May 27, 2026
Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain.

|Mar 03, 2026
Nationwide Mammographic Screening Among a Large Population of Underserved Subgroups.

Elizabeth J Cathcart-Rake, Viengneesee Thao, Jennifer Le-Rademacher

|Aug 28, 2025
The Impact of Design Misspecifications on Survival Outcomes in Cancer Clinical Trials.

Fang-Shu Ou, Tyler Zemla, Jennifer G Le-Rademacher

|Nov 27, 2024
Deficit accumulation frailty index and treatment tolerability in AML: data from CALGB 11001 and 11002 (Alliance).

Catherine Lai, Minji Lee, Olivia Bobek

|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.

Saurabh Zanwar, Jennifer Le-Rademacher, Eric Durot

|Jan 20, 2024
The symbolic two-step method applied to cancer care delivery research: Safeguarding against designing an underpowered cluster randomized trial with a continuous outcome by accounting for the imprecision in the within- and between-center variation.

David Zahrieh, Blaize W Kandler, Jennifer Le-Rademacher

Pageof 5

Frequent Collaborators

4 joint publications

Aminah Jatoi

3 joint publications

Heidi Klepin

3 joint publications

Charles Loprinzi

3 joint publications

Kathryn J Ruddy